Literature DB >> 15888768

ESMO recommendations for the application of hematopoietic growth factors.

R Greil1, L M Jost.   

Abstract

Mesh:

Substances:

Year:  2005        PMID: 15888768     DOI: 10.1093/annonc/mdi813

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.

Authors:  Hiroshi Nokihara; Yasuhide Yamada; Yutaka Fujiwara; Noboru Yamamoto; Hiroshi Wakui; Shinji Nakamichi; Satoru Kitazono; Kohei Inoue; Akiko Harada; Tillmann Taube; Yoshito Takeuchi; Tomohide Tamura
Journal:  Invest New Drugs       Date:  2015-12-02       Impact factor: 3.850

2.  Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.

Authors:  Alfredo Carrato; Luis Paz-Ares Rodríguez; Alvaro Rodríguez Lescure; Ana M Casas Fernández de Tejerina; Eduardo Díaz Rubio García; Pedro Pérez Segura; Manuel Constenla Figueiras; Rocío García Carbonero; José Gómez Codina; Ana Lluch Hernández; José Pablo Maroto Rey; Miguel Martín Jiménez; José Ignacio Mayordomo Cámara; José Andrés Moreno Nogueira; Antonio Rueda Domínguez
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

3.  Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.

Authors:  M Debled; N Houédé; N Madranges; C Donamaria; A Floquet; M Durand; Louis Mauriac
Journal:  Br J Cancer       Date:  2007-11-13       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.